Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E- EPS (ttm)-0.24 Insider Own0.41% Shs Outstand1.26B Perf Week-6.11%
Market Cap77.09B Forward P/E8.68 EPS next Y6.98 Insider Trans-0.64% Shs Float1.25B Perf Month-5.70%
Income-257.00M PEG- EPS next Q1.96 Inst Own81.50% Short Float1.55% Perf Quarter-20.59%
Sales22.17B P/S3.48 EPS this Y1.10% Inst Trans0.12% Short Ratio2.15 Perf Half Y-25.53%
Book/sh14.36 P/B4.22 EPS next Y-0.14% ROA-0.40% Target Price78.42 Perf Year-7.15%
Cash/sh14.86 P/C4.08 EPS next 5Y0.59% ROE-1.20% 52W Range59.85 - 85.97 Perf YTD-6.82%
Dividend2.72 P/FCF14.90 EPS past 5Y-10.50% ROI9.50% 52W High-29.93% Beta0.52
Dividend %4.49% Quick Ratio2.20 Sales past 5Y-2.00% Gross Margin78.60% 52W Low0.64% ATR1.35
Employees11800 Current Ratio2.30 Sales Q/Q-9.50% Oper. Margin-4.30% RSI (14)32.88 Volatility1.96% 1.84%
OptionableYes Debt/Eq1.34 EPS Q/Q-280.70% Profit Margin-1.20% Rel Volume0.84 Prev Close60.55
ShortableYes LT Debt/Eq1.17 EarningsOct 28 AMC Payout- Avg Volume9.02M Price60.24
Recom2.50 SMA20-4.12% SMA50-7.05% SMA200-15.36% Volume3,308,591 Change-0.51%
Sep-30-20Resumed Jefferies Buy $78
Sep-15-20Upgrade Maxim Group Hold → Buy $88
Jul-31-20Reiterated Wells Fargo Equal Weight $87 → $76
Jul-31-20Reiterated SunTrust Hold $73 → $74
Jul-31-20Reiterated RBC Capital Mkts Outperform $89 → $87
Jul-31-20Reiterated Piper Sandler Overweight $90 → $85
Jul-31-20Reiterated Morgan Stanley Equal-Weight $80 → $79
Jul-31-20Reiterated Credit Suisse Neutral $75 → $73
Jul-20-20Upgrade Credit Suisse Underperform → Neutral $64 → $75
Jun-03-20Upgrade SVB Leerink Mkt Perform → Outperform $85 → $94
May-26-20Upgrade SunTrust Sell → Hold $73
May-01-20Downgrade SunTrust Hold → Sell $70
May-01-20Downgrade Raymond James Outperform → Mkt Perform
May-01-20Downgrade JP Morgan Overweight → Neutral
Apr-27-20Downgrade UBS Buy → Neutral $77 → $80
Apr-20-20Downgrade Wells Fargo Overweight → Equal Weight $87
Apr-20-20Downgrade BMO Capital Markets Outperform → Market Perform $79
Apr-17-20Downgrade CFRA Hold → Sell
Mar-31-20Initiated Wolfe Research Peer Perform
Mar-20-20Upgrade Piper Sandler Neutral → Overweight $70 → $90
Oct-21-20 12:00PM  
10:37AM  
07:44AM  
07:01AM  
06:09AM  
Oct-20-20 05:45PM  
02:55PM  
02:11PM  
09:02AM  
08:00AM  
05:30AM  
02:30AM  
Oct-19-20 04:32PM  
02:40PM  
01:35PM  
11:00AM  
08:30AM  
Oct-18-20 06:42AM  
Oct-17-20 03:57AM  
Oct-16-20 03:38PM  
03:36PM  
03:24PM  
01:53PM  
01:25PM  
11:22AM  
11:04AM  
09:56AM  
09:33AM  
08:02AM  
07:57AM  
07:28AM  
06:52AM  
06:35AM  
06:24AM  
06:13AM  
06:04AM  
04:05AM  
02:10AM  
Oct-15-20 08:50PM  
05:00PM  
04:25PM  
03:56PM  
09:41AM  
Oct-14-20 04:44PM  
04:29PM  
04:01PM  
10:48AM  
10:10AM  
08:30AM  
07:32AM  
Oct-13-20 05:45PM  
04:24PM  
03:20PM  
03:10PM  
12:48PM  
11:29AM  
08:09AM  
Oct-12-20 05:23PM  
03:12PM  
10:45AM  
09:55AM  
09:52AM  
09:15AM  
07:20AM  
Oct-11-20 09:32AM  
07:06AM  
07:04AM  
Oct-10-20 07:00AM  
Oct-09-20 08:43PM  
04:16PM  
04:15PM  
12:48PM  
12:35PM  
11:48AM  
10:12AM  
10:12AM  
10:02AM  
05:45AM  
Oct-08-20 10:13PM  
10:10PM  
05:33PM  
05:05PM  
04:14PM  
12:22PM  
08:31AM  
07:52AM  
05:59AM  
04:38AM  
03:00AM  
Oct-07-20 04:34PM  
12:57PM  
11:27AM  
10:24AM  
Oct-06-20 05:45PM  
12:39PM  
10:04AM  
08:15AM  
06:08AM  
Oct-05-20 05:47PM  
04:28PM  
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Whitley Richard JamesDirectorOct 01Option Exercise0.001,434031,122Oct 05 07:09 PM
Parsey MerdadChief Medical OfficerAug 17Sale68.3218212,4340Aug 19 12:53 PM
Mercier JohannaChief Commercial OfficerJul 24Option Exercise0.007,50507,505Jul 28 06:47 PM
Rodriguez JavierDirectorJun 23Sale75.5018914,2700Jun 25 01:51 PM
Dickinson Andrew DEVP, Chief Financial OfficerJun 10Option Exercise0.003,646015,046Jun 12 03:28 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Option Exercise39.7613,210525,22527,854May 07 06:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Sale79.2313,2101,046,64014,644May 07 06:02 PM
Cogan John FrancisDirectorMay 04Option Exercise19.632,41647,42657,276May 05 04:28 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Option Exercise66.3611,486762,21123,685May 06 06:40 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Sale80.0912,264982,22011,421May 06 06:40 PM
Cogan John FrancisDirectorMay 04Sale81.752,416197,50854,860May 05 04:28 PM
Cogan John FrancisDirectorApr 27Option Exercise19.632,41347,36757,273Apr 29 07:28 PM
Cogan John FrancisDirectorApr 27Sale79.902,413192,79954,860Apr 29 07:28 PM
Cogan John FrancisDirectorApr 20Option Exercise19.632,41347,36757,273Apr 21 07:42 PM
Cogan John FrancisDirectorApr 20Sale83.002,413200,27954,860Apr 21 07:42 PM
Cogan John FrancisDirectorApr 13Option Exercise19.632,41347,36757,273Apr 14 03:52 PM
Cogan John FrancisDirectorApr 13Sale75.902,413183,14754,860Apr 14 03:52 PM
Cogan John FrancisDirectorApr 06Option Exercise19.632,41347,36757,273Apr 07 05:34 PM
Cogan John FrancisDirectorApr 06Sale79.522,413191,88254,860Apr 07 05:34 PM
Cogan John FrancisDirectorMar 30Option Exercise19.632,41347,36757,273Mar 31 03:00 PM
Cogan John FrancisDirectorMar 30Sale75.352,413181,82054,860Mar 31 03:00 PM
Cogan John FrancisDirectorMar 23Option Exercise19.632,41347,36757,273Mar 24 08:42 PM
Cogan John FrancisDirectorMar 23Sale75.272,413181,62754,860Mar 24 08:42 PM
Cogan John FrancisDirectorMar 16Option Exercise19.632,41347,36757,273Mar 17 08:01 PM
Cogan John FrancisDirectorMar 16Sale67.262,413162,29854,860Mar 17 08:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Option Exercise24.302,95071,67017,594Mar 12 08:30 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Sale75.552,950222,87314,644Mar 12 08:30 PM
Cogan John FrancisDirectorMar 09Option Exercise19.632,41347,36757,273Mar 10 09:16 PM
Cogan John FrancisDirectorMar 09Sale77.972,413188,14254,860Mar 10 09:16 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 02Sale70.8810,441740,01414,644Mar 03 07:40 PM
Lofton Kevin EDirectorFeb 24Option Exercise19.6321,720426,36486,579Feb 25 05:13 PM
WILSON GAYLE EDirectorFeb 10Option Exercise19.6321,720426,364148,502Feb 11 07:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Option Exercise24.302,95071,67027,640Feb 12 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Sale69.322,950204,49424,690Feb 12 06:25 PM
WILSON GAYLE EDirectorFeb 10Sale67.7221,7201,470,878126,782Feb 11 07:02 PM
WOLD OLSEN PERDirectorFeb 07Option Exercise20.6520,282418,722118,136Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 07Sale70.001,42699,82024,690Feb 10 07:00 PM
WOLD OLSEN PERDirectorFeb 07Sale69.0020,2821,399,45897,854Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Option Exercise40.565,000202,80029,690Feb 10 07:00 PM
WOLD OLSEN PERDirectorFeb 06Option Exercise19.6321,720426,364119,574Feb 10 06:25 PM
WOLD OLSEN PERDirectorFeb 06Sale68.1221,7201,479,60597,854Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Sale68.185,000340,90124,690Feb 10 07:00 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Option Exercise24.302,95071,67020,014Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Sale64.632,950190,65917,064Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Option Exercise24.305,900143,34122,964Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Sale65.775,900388,04317,064Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 25Option Exercise40.5615,000608,40032,064Nov 26 02:14 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 25Sale66.8515,0001,002,80917,064Nov 26 02:14 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 19Option Exercise24.3010,000242,95027,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 19Sale64.9110,000649,06217,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 18Option Exercise24.3010,000242,95027,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 18Sale63.8510,000638,50017,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 05Sale66.062,095138,40417,826Nov 07 08:04 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Option Exercise16.892,40040,53623,921Nov 05 08:21 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Sale64.524,000258,09919,921Nov 05 08:21 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecOct 28Sale63.315,677359,41221,521Oct 30 08:35 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.